These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 37069321)

  • 1. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease.
    Verstockt B; Salas A; Sands BE; Abraham C; Leibovitzh H; Neurath MF; Vande Casteele N;
    Nat Rev Gastroenterol Hepatol; 2023 Jul; 20(7):433-446. PubMed ID: 37069321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of IL-23: What is in the Pipeline?
    Parigi TL; Iacucci M; Ghosh S
    J Crohns Colitis; 2022 May; 16(Supplement_2):ii64-ii72. PubMed ID: 35553666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-interleukin-23 agents for the treatment of ulcerative colitis.
    Hanžel J; D'Haens GR
    Expert Opin Biol Ther; 2020 Apr; 20(4):399-406. PubMed ID: 31760827
    [No Abstract]   [Full Text] [Related]  

  • 5. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
    Wong U; Cross RK
    Expert Opin Investig Drugs; 2019 May; 28(5):473-479. PubMed ID: 30884245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?
    Ma C; Panaccione R; Khanna R; Feagan BG; Jairath V
    Best Pract Res Clin Gastroenterol; 2019; 38-39():101604. PubMed ID: 31327402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
    Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
    [No Abstract]   [Full Text] [Related]  

  • 9. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
    Deepak P; Sandborn WJ
    Gastroenterol Clin North Am; 2017 Sep; 46(3):603-626. PubMed ID: 28838418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease.
    Macaluso FS; Orlando A; Cottone M
    Expert Opin Biol Ther; 2019 Feb; 19(2):89-98. PubMed ID: 30571147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
    Deepak P; Loftus EV
    Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting IL-23 for IBD: Rationale and Progress to Date.
    Vuyyuru SK; Shackelton LM; Hanzel J; Ma C; Jairath V; Feagan BG
    Drugs; 2023 Jul; 83(10):873-891. PubMed ID: 37266801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23.
    Steere B; Beidler C; Martin A; Bright S; Kikly K; Benschop RJ
    J Pharmacol Exp Ther; 2023 Nov; 387(2):180-187. PubMed ID: 37714687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of IL-23 Inhibitors in Crohn's Disease.
    Fanizza J; D'Amico F; Lusetti F; Fasulo E; Allocca M; Furfaro F; Zilli A; Parigi TL; Radice S; Peyrin-Biroulet L; Danese S; Fiorino G
    J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease.
    Almradi A; Hanzel J; Sedano R; Parker CE; Feagan BG; Ma C; Jairath V
    BioDrugs; 2020 Dec; 34(6):713-721. PubMed ID: 33105016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges.
    Noviello D; Mager R; Roda G; Borroni RG; Fiorino G; Vetrano S
    Front Immunol; 2021; 12():611256. PubMed ID: 34079536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.
    Fuss IJ; Becker C; Yang Z; Groden C; Hornung RL; Heller F; Neurath MF; Strober W; Mannon PJ
    Inflamm Bowel Dis; 2006 Jan; 12(1):9-15. PubMed ID: 16374252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting IL-23 in Crohn's disease.
    Sedda S; Bevivino G; Monteleone G
    Expert Rev Clin Immunol; 2018 Nov; 14(11):907-913. PubMed ID: 30223688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IL-12/23 in Crohn's disease: bench and bedside.
    Niederreiter L; Adolph TE; Kaser A
    Curr Drug Targets; 2013 Nov; 14(12):1379-84. PubMed ID: 24138637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of ustekinumab in treatment of ulcerative colitis: a narrative review.
    Grova M; Vitello A; Mannino M; Casà A; Renna S; Macaluso FS; Orlando A
    Immunotherapy; 2023 Dec; 15(18):1539-1552. PubMed ID: 38018475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.